{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+10+mg+tablet.", "query": { "intervention": "Rosuvastatin 10 mg tablet." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+10+mg+tablet.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T13:20:15.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00249912", "title": "Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Lapaquistat acetate and rosuvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2005-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-05-24", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249912" }, { "nct_id": "NCT06538649", "title": "Effect of Statins on Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Crohn's Ileocolitis", "Crohn Disease" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2024-12-12", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06538649" }, { "nct_id": "NCT03864042", "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Melanoma" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "rosuvastatin", "type": "DRUG" }, { "name": "bupropion immediate release (IR)", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-01-02", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hopkins", "state": "Minnesota" }, { "city": "Maple Grove", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864042" }, { "nct_id": "NCT06948747", "title": "A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5004", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2025-05-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948747" }, { "nct_id": "NCT02371603", "title": "Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "GSK1278863 25 mg Tablet", "type": "DRUG" }, { "name": "Pioglitazone 15 mg Tablet", "type": "DRUG" }, { "name": "Rosuvastatin 10 mg Tablet", "type": "DRUG" }, { "name": "Trimethoprim 100 mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2015-02-11", "completion_date": "2015-08-12", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02371603" }, { "nct_id": "NCT06533280", "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Part A, C and D: VH3739937 500 mg", "type": "DRUG" }, { "name": "Part A: VH3739937 100 mg", "type": "DRUG" }, { "name": "Part A and C: Placebo", "type": "DRUG" }, { "name": "Part B: Treatment A", "type": "DRUG" }, { "name": "Part B: Treatment B", "type": "DRUG" }, { "name": "Part B: Treatment C", "type": "DRUG" }, { "name": "Part B: Treatment D", "type": "DRUG" }, { "name": "Part B: Treatment E", "type": "DRUG" }, { "name": "Part D: Probe cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-08-02", "completion_date": "2024-08-14", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533280" }, { "nct_id": "NCT01751074", "title": "To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atherosclerosis" ], "interventions": [ { "name": "Rosuvastatin 10 mg", "type": "DRUG" }, { "name": "Darapladib 160 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "20 Years to 64 Years" }, "enrollment_count": 18, "start_date": "2012-12-17", "completion_date": "2013-03-14", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01751074" }, { "nct_id": "NCT04608344", "title": "Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2020-11-04", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608344" }, { "nct_id": "NCT03699774", "title": "Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Pharmacokinetics in Healthy Volunteers" ], "interventions": [ { "name": "DS-8500a", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 24, "start_date": "2015-05-12", "completion_date": "2015-07-06", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699774" }, { "nct_id": "NCT06186622", "title": "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Obese", "Overweight" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Sodium Bicarbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2024-01-02", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-01T13:20:15.672Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186622" } ] }